Liposomal PEA complex

Dosage and use

• Dosage
  • based on scientific literature.
  • <12 years old only under medical supervision
  • 12-18 years
    • maintenance 1x daily 1 capsules
    • increased need 2x daily 1 capsules
  • Adults
    • maintenance 1x daily 1 capsules
    • increased need 2x daily 1 capsules
    • Therapeutic dosage (max 4-6 weeks in consultation with doctor or therapist) 2x daily 2 capsules
• Manual
  • Preferably with a meal
  • Morning and/or afternoon
    
  • Store dry, closed and at room temperature.
• Allergy information
  • Allergen-free: free from gluten, soy, nuts, egg, fish, shellfish
• Contraindications
  • Caution in case of anti-coagulation (mild activity Boswellia)
  • Do not use during pregnancy/breastfeeding without consultation
  • Do not use if allergy to ingredients
• Side effects
  • Mild: dry mouth, mild nausea, soft stools.
  • Rare: skin reaction in Boswellia hypersensitivity.
• Interactions
  • Boswellia (particularly AKBA) selectively inhibits 5-lipoxygenase (5-LOX), reducing the production of leukotrienes (LTB4, LTC4). This may enhance the action of drugs that target leukotriene pathways (such as montelukast).
  • Boswellia also has mild inhibition of COX-1/2, which could theoretically have an additive effect when used with NSAIDs. There is evidence that Boswellia may affect certain phase I enzymes, including mild inhibition of CYP subtypes, but clinical relevance is limited.
  • PEA works via PPAR-α activation, which modulates inflammatory pathways such as NF-κB and mast cell activity. It does not directly affect CYP enzymes, but can affect sensitivity to painkillers (synergistically).
  • When using strong immunomodulators, anticoagulant medication or polypharmacy (e.g. oncology, rheumatology), consultation with a doctor is desirable.